265 related articles for article (PubMed ID: 26659654)
1. Hippocalcin-like 1 suppresses hepatocellular carcinoma progression by promoting p21(Waf/Cip1) stabilization by activating the ERK1/2-MAPK pathway.
Zhang Y; Liu Y; Duan J; Yan H; Zhang J; Zhang H; Fan Q; Luo F; Yan G; Qiao K; Liu J
Hepatology; 2016 Mar; 63(3):880-97. PubMed ID: 26659654
[TBL] [Abstract][Full Text] [Related]
2. Simvastatin-induced cell cycle arrest through inhibition of STAT3/SKP2 axis and activation of AMPK to promote p27 and p21 accumulation in hepatocellular carcinoma cells.
Wang ST; Ho HJ; Lin JT; Shieh JJ; Wu CY
Cell Death Dis; 2017 Feb; 8(2):e2626. PubMed ID: 28230855
[TBL] [Abstract][Full Text] [Related]
3. HJURP promotes hepatocellular carcinoma proliferation by destabilizing p21 via the MAPK/ERK1/2 and AKT/GSK3β signaling pathways.
Chen T; Huang H; Zhou Y; Geng L; Shen T; Yin S; Zhou L; Zheng S
J Exp Clin Cancer Res; 2018 Aug; 37(1):193. PubMed ID: 30111352
[TBL] [Abstract][Full Text] [Related]
4. SKP2 and CKS1 promote degradation of cell cycle regulators and are associated with hepatocellular carcinoma prognosis.
Calvisi DF; Ladu S; Pinna F; Frau M; Tomasi ML; Sini M; Simile MM; Bonelli P; Muroni MR; Seddaiu MA; Lim DS; Feo F; Pascale RM
Gastroenterology; 2009 Nov; 137(5):1816-26.e1-10. PubMed ID: 19686743
[TBL] [Abstract][Full Text] [Related]
5. Notch1 signaling inhibits growth of human hepatocellular carcinoma through induction of cell cycle arrest and apoptosis.
Qi R; An H; Yu Y; Zhang M; Liu S; Xu H; Guo Z; Cheng T; Cao X
Cancer Res; 2003 Dec; 63(23):8323-9. PubMed ID: 14678992
[TBL] [Abstract][Full Text] [Related]
6. FBXO22 promotes the development of hepatocellular carcinoma by regulating the ubiquitination and degradation of p21.
Zhang L; Chen J; Ning D; Liu Q; Wang C; Zhang Z; Chu L; Yu C; Liang HF; Zhang B; Chen X
J Exp Clin Cancer Res; 2019 Feb; 38(1):101. PubMed ID: 30808376
[TBL] [Abstract][Full Text] [Related]
7. Early mitotic inhibitor-1, an anaphase-promoting complex/cyclosome inhibitor, can control tumor cell proliferation in hepatocellular carcinoma: correlation with Skp2 stability and degradation of p27(Kip1).
Zhao Y; Tang Q; Ni R; Huang X; Wang Y; Lu C; Shen A; Wang Y; Li C; Yuan Q; Chen H; Cheng C; He S
Hum Pathol; 2013 Mar; 44(3):365-73. PubMed ID: 22995332
[TBL] [Abstract][Full Text] [Related]
8. Ku80 functions as a tumor suppressor in hepatocellular carcinoma by inducing S-phase arrest through a p53-dependent pathway.
Wei S; Xiong M; Zhan DQ; Liang BY; Wang YY; Gutmann DH; Huang ZY; Chen XP
Carcinogenesis; 2012 Mar; 33(3):538-47. PubMed ID: 22226916
[TBL] [Abstract][Full Text] [Related]
9. Regulation of Akt/FoxO3a/Skp2 Axis Is Critically Involved in Berberine-Induced Cell Cycle Arrest in Hepatocellular Carcinoma Cells.
Li F; Dong X; Lin P; Jiang J
Int J Mol Sci; 2018 Jan; 19(2):. PubMed ID: 29360760
[TBL] [Abstract][Full Text] [Related]
10. 1,25(OH)2D3 inhibits the progression of hepatocellular carcinoma via downregulating HDAC2 and upregulating P21(WAFI/CIP1).
Huang J; Yang G; Huang Y; Kong W; Zhang S
Mol Med Rep; 2016 Feb; 13(2):1373-80. PubMed ID: 26676829
[TBL] [Abstract][Full Text] [Related]
11. RN181 suppresses hepatocellular carcinoma growth by inhibition of the ERK/MAPK pathway.
Wang S; Huang X; Li Y; Lao H; Zhang Y; Dong H; Xu W; Li JL; Li M
Hepatology; 2011 Jun; 53(6):1932-42. PubMed ID: 21391225
[TBL] [Abstract][Full Text] [Related]
12. Mucin1 shifts Smad3 signaling from the tumor-suppressive pSmad3C/p21(WAF1) pathway to the oncogenic pSmad3L/c-Myc pathway by activating JNK in human hepatocellular carcinoma cells.
Li Q; Liu G; Yuan H; Wang J; Guo Y; Chen T; Zhai R; Shao D; Ni W; Tai G
Oncotarget; 2015 Feb; 6(6):4253-65. PubMed ID: 25714018
[TBL] [Abstract][Full Text] [Related]
13. [Expression of proteins in p53 (p14ARF-mdm2-p53-p21WAF/CIP1) pathway and their significance in exocrine pancreatic carcinoma].
Yu GZ; Zhu MH; Ni CR; Li FM; Zheng JM; Gong ZJ
Zhonghua Bing Li Xue Za Zhi; 2004 Apr; 33(2):130-4. PubMed ID: 15132849
[TBL] [Abstract][Full Text] [Related]
14. Expression of p27(KIP1) and p21(WAF1/CIP1) in primary hepatocellular carcinoma: clinicopathologic correlation and survival analysis.
Qin LF; Ng IO
Hum Pathol; 2001 Aug; 32(8):778-84. PubMed ID: 11521219
[TBL] [Abstract][Full Text] [Related]
15. Inactivation of the CRL4-CDT2-SET8/p21 ubiquitylation and degradation axis underlies the therapeutic efficacy of pevonedistat in melanoma.
Benamar M; Guessous F; Du K; Corbett P; Obeid J; Gioeli D; Slingluff CL; Abbas T
EBioMedicine; 2016 Aug; 10():85-100. PubMed ID: 27333051
[TBL] [Abstract][Full Text] [Related]
16. HBx-related long non-coding RNA DBH-AS1 promotes cell proliferation and survival by activating MAPK signaling in hepatocellular carcinoma.
Huang JL; Ren TY; Cao SW; Zheng SH; Hu XM; Hu YW; Lin L; Chen J; Zheng L; Wang Q
Oncotarget; 2015 Oct; 6(32):33791-804. PubMed ID: 26393879
[TBL] [Abstract][Full Text] [Related]
17. Ubiquitination of p21Cip1/WAF1 by SCFSkp2: substrate requirement and ubiquitination site selection.
Wang W; Nacusi L; Sheaff RJ; Liu X
Biochemistry; 2005 Nov; 44(44):14553-64. PubMed ID: 16262255
[TBL] [Abstract][Full Text] [Related]
18. IL-37 suppresses hepatocellular carcinoma growth by converting pSmad3 signaling from JNK/pSmad3L/c-Myc oncogenic signaling to pSmad3C/P21 tumor-suppressive signaling.
Liu R; Tang C; Shen A; Luo H; Wei X; Zheng D; Sun C; Li Z; Zhu D; Li T; Wu Z
Oncotarget; 2016 Dec; 7(51):85079-85096. PubMed ID: 27835881
[TBL] [Abstract][Full Text] [Related]
19. N-myc downstream regulated gene1/Cap43 overexpression suppresses tumor growth by hepatic cancer cells through cell cycle arrest at the G0/G1 phase.
Akiba J; Murakami Y; Noda M; Watari K; Ogasawara S; Yoshida T; Kawahara A; Sanada S; Yasumoto M; Yamaguchi R; Kage M; Kuwano M; Ono M; Yano H
Cancer Lett; 2011 Nov; 310(1):25-34. PubMed ID: 21775055
[TBL] [Abstract][Full Text] [Related]
20. Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver.
Yeganeh M; Gui Y; Kandhi R; Bobbala D; Tobelaim WS; Saucier C; Yoshimura A; Ferbeyre G; Ramanathan S; Ilangumaran S
Oncogene; 2016 Aug; 35(32):4200-11. PubMed ID: 26725321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
